Filing Details

Accession Number:
0001179110-13-012864
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-08-08 20:21:28
Reporting Period:
2013-08-06
Filing Date:
2013-08-08
Accepted Time:
2013-08-08 20:21:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1012140 Onyx Pharmaceuticals Inc ONXX Biological Products, (No Disgnostic Substances) (2836) 943154463
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1312622 I Kaye Foster-Cheek C/o Onyx Pharmaceuticals, Inc.
249 E. Grand Ave.
South San Francisco CA 94080
Svp, Global Human Resources No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-08-06 4,740 $26.38 31,806 No 4 M Direct
Common Stock Acquisiton 2013-08-06 1,750 $35.18 33,556 No 4 M Direct
Common Stock Acquisiton 2013-08-06 2,388 $37.68 35,944 No 4 M Direct
Common Stock Disposition 2013-08-06 8,378 $132.76 27,566 No 4 S Direct
Common Stock Disposition 2013-08-06 500 $133.68 27,066 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2013-08-06 4,740 $0.00 4,740 $26.38
Common Stock Stock Option (Right to Buy) Disposition 2013-08-06 1,750 $0.00 1,750 $35.18
Common Stock Stock Option (Right to Buy) Disposition 2013-08-06 2,388 $0.00 2,388 $37.68
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
32,832 2020-09-30 No 4 M Direct
11,667 2021-03-31 No 4 M Direct
25,466 2022-03-29 No 4 M Direct
Footnotes
  1. Shares sold pursuant to a 10b5-1 plan.
  2. The shares were sold at prices ranging from $132.49 to $133.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. Twenty-Five percent of the shares subject to the option vest and become exercisable one year from the date of grant and vest and become exercisable at a rate of 1/48th per month thereafter.
  4. 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.